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MVT is found in as few as one in 1000 laparotomies. In a
recent report by Rhee et al,5 MVT comprised only 6.2% of
all patients treated for mesenteric ischemia.
The objectives of this study were to evaluate underly-
ing individual patient disease histories for insights into
predisposing factors, to evaluate the methods used to
obtain early diagnosis of this clinical entity, and to assess
the long-term outcome of patients with MVT.
PATIENTS
Thirty-one patients in whom MVT was diagnosed
were encountered in the 14 years between 1985 and
1999. Charts were retrospectively reviewed, and patients
were contacted for follow-up.
Patient demographics, presenting symptoms, past
medical history, laboratory and radiologic examination
results, hospital course, and late clinical outcome were
recorded. Short-term follow-up was obtained until the
death or hospital discharge of the patient. Long-term fol-
low-up was obtained from late outpatient office visit
records and telephone interviews. Patients lost to follow-
up were tracked through Social Security databases and the
Social Security Death Index. Of the 31 patients with doc-
umented MVT, 15 were men and 16 were women. Ages
ranged from 22 to 80 years (average, 49.1 years).
Mesenteric venous thrombosis (MVT) is an uncom-
mon cause of mesenteric ischemia. It was first recognized
more than 100 years ago by Eliot,1 who described intesti-
nal gangrene resulting from mesenteric venous occlusion.
In 1913, Trotter2 reported that 41% of patients with
mesenteric ischemia had MVT. It was Warren and
Eberhardt’s historic report in 19353 that helped to estab-
lish MVT as a distinct clinical entity. They reported a mor-
tality rate of 34%. Additionally, Warren and Eberhardt
found that only 5% of patients who did not undergo sur-
gical treatment survived. In the last decade, new reports
have helped define this rare entity. Kazmers4 inferred that
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Objective: Mesenteric venous thrombosis (MVT) and its clinical spectrum have become better defined following
improvements in diagnostic imaging. Historically, MVT has been described as a morbid clinical entity, but this may not
necessarily be true. Often, an underlying disease process that predisposes a patient to MVT can be found and poten-
tially treated. This study was designed to evaluate the diagnostics and management of MVT and to review long-term
results of treatment.
Patients: Thirty-one patients in whom MVT was diagnosed between 1985 and 1999 were retrospectively reviewed.
Survivors were contacted for follow-up. There were 15 men and 16 women. Ages ranged from 22 to 80 years (mean,
49.1 years). Thirteen patients had documented hypercoagulability, 10 had a history of previous abdominal surgery, 6
had a prior thrombotic episode, and 4 had a history of cancer. MVT presented as abdominal pain (84%), diarrhea
(42%), and nausea/vomiting (32%). Computed tomography (CT) was considered diagnostic in 18 (90%) of 20 patients
who underwent the test. CT diagnosed MVT in 15 (100%) of 15 patients presenting with vague abdominal pain or
diarrhea. Angiography demonstrated MVT in only five (55.5%) of nine patients.
Results: Seven of 31 patients died within 30 days (< 30-day mortality rate, 23%). Twenty-two patients (72%) were ini-
tially treated with heparin. Nine patients were not heparinized: four of them died, and two were later given warfarin
sodium (Coumadin). Of the 31 patients, only one received lytic therapy. Three patients became symptom free without
anticoagulation. Ten patients (32%) underwent bowel resection. Overall, 19 (79%) of 24 survivors were treated with
long-term warfarin therapy. Long-term follow-up was obtained in 24 patients (mean, 57.7 months). Twenty-one (88%)
of 24 survived in follow-up.
Conclusion: The diagnosis of MVT should be suspected when acute abdominal symptoms develop in patients with prior
thrombotic episodes or a documented coagulopathy. CT scanning appears to be the primary diagnostic test of choice.
Anticoagulation is recommended. If diagnosed and treated early, MVT is not likely to progress to gangrenous bowel.
Recent mortality rates for MVT are lower than previously published, perhaps because of earlier diagnosis and aggres-
sive treatment or possibly because we now readily diagnose a more benign form of the disease, which is due to wide-
spread use of CT scanning. (J Vasc Surg 2001;34:680-4.)
RESULTS
Clinical presentation. MVT presented as abdominal
pain in 84% of patients. Of those with abdominal pain, five
patients (16%) presented with peritoneal signs and 21
patients (68%) presented with vague abdominal pain.
Other common symptoms on presentation included diar-
rhea (42%), nausea/vomiting (32%), lower gastrointesti-
nal bleeding (19%), malaise (16%), and upper
gastrointestinal bleeding (10%).
Diagnostic evaluation. MVT was diagnosed primar-
ily and definitively on the basis of the venous phase of a
selective mesenteric arteriogram (n = 5), mesenteric
duplex ultrasonography (n = 2), contrast-enhanced com-
puted tomography (CT) scan with 50-second delay
venous phase (n = 18), and magnetic resonance imaging
(MRI) (n = 1). Additionally, five patients had the diagno-
sis confirmed during exploratory laparotomy. Typical pos-
itive findings of a CT scan (Fig 1) or an MRI (Fig 2)
consisted of enlargement of the thrombosed vein, a cen-
tral area of low attenuation representing intraluminal
thrombus, and the vein wall sharply delineated by a hyper-
lucent or high intensity rim of tissue.
CT scans were diagnostic in 18 (90%) of 20 patients
who underwent the test. Fifteen of 20 patients clearly
demonstrated a mesenteric venous filling defect, whereas
three patients had CT findings including edematous or
dilated small bowel or mesenteric stranding, which
strongly suggested the diagnosis of MVT. Two patients
were found to have only mildly dilated loops of small
bowel and peritoneal fluid; as such, no final CT diagnosis
of MVT was made. Of these two patients, one later had a
diagnosis with MVT during exploratory laparotomy, and
one had a diagnosis with MRI and was observed. Other
CT findings included free fluid (65%), an enlarged, dilated
superior mesenteric vein (45%), mesenteric edema or
“stranding” (35%), bowel wall thickening or edema
(25%), and dilated loops of small bowel (20%). CT diag-
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nosed MVT in all patients who presented with abdominal
pain and who underwent the test. Angiography diagnosed
MVT in five (55.5%) of nine patients.
Associated conditions. Most patients had throm-
botic tendencies. Although not all patients underwent
complete blood testing, a hypercoagulable state was ulti-
mately diagnosed in 13 patients (42%). Twelve of 13
patients were found to have protein C, protein S, or
antithrombin III deficiency. A single patient had isolated
activated protein C resistance. Six patients had prior
thrombotic episodes, including deep venous thrombosis
(5) or arterial thrombosis (1). Four patients had a history
of cancer, including one case each of acute lymphocytic
leukemia, B-cell lymphoproliferative disorder, adenocarci-
noma of the small bowel, and bladder carcinoma. Five
patients had previously undergone a splenectomy (mean
platelet count, 487,000; range, 159,000-919,000).
Clinical outcome. The five patients with peritonitis
underwent immediate exploratory laparotomy with the
goal of preventing or limiting bowel gangrene and its
complications. A total of 10 patients (32%) ultimately
underwent surgical exploration and bowel resection. One
patient in this group underwent superior mesenteric
venous thrombectomy along with bowel resection. The
extent of bowel resection ranged from 20 cm of jejunum
to the entire jejunum and half the ileum. Of note, only
half of the patients who required bowel resection had pro-
gressed to frank peritonitis. One patient underwent a neg-
ative exploratory laparotomy. The overall mortality rate
for surgery was 27% (3/11).
Seven of 31 patients died within 30 days (< 30-day
mortality rate, 23%). Only two patients died as a result of
bowel infarction. Three died of cirrhosis, and two experi-
enced multisystem organ failure. Twenty-two patients
(72%) were treated with heparin once the diagnosis of
MVT had been confirmed. One patient also received lytic
therapy through the superior mesenteric artery for portal
Fig 1. CT scan showing enlargement of superior mesenteric vein
with central area of low attenuation representing intraluminal
thrombus and vein wall sharply delineated by rim of tissue (white
arrow).
Fig 2. MRI showing dilation of superior mesenteric vein with
central area of low attenuation and vein wall surrounded by
hyperlucent or high intensity rim of tissue (white arrow).
vein and superior MVT. This patient required no further
treatment and remained symptom free on late follow-up.
Nine patients were not initially heparinized: 4 died; 2
were later given warfarin sodium (Coumadin); and 3, who
had a subacute presentation, did not receive anticoagula-
tion. Four of the patients were not initially heparinized
because they had recently undergone surgery or had
recently experienced gastrointestinal bleeding. Overall, 19
(79%) of 24 survivors were treated with long-term war-
farin therapy.
Long-term follow-up. Long-term data were obtained
on all 24 of the patients who survived the initial hospital-
ization (mean, 57.7 months). Twenty-one (88%) of 24
patients survived long-term. One late death resulted from
pancreatic cancer at 12 months, one from myocardial
infarction at 6 months, and one from metastatic small
bowel cancer at 12 months. All 22 long-term survivors were
symptom free at last follow-up. Nineteen were still taking
Coumadin.
DISCUSSION
This study describes patient outcome in a large single
center series of patients with MVT. MVT usually occurs
without gangrenous bowel. Presenting symptoms vary
from a benign, mildly symptomatic state to abdominal ca-
tastrophe. Some form of abdominal pain or discomfort is
found in most of the patients, although MVT as an inci-
dental CT finding can occur. Abdominal distention, diar-
rhea, nausea, or vomiting may also be early complaints.
Because of the nonspecific presentation, the diagnosis of
MVT can remain elusive and may not be recognized until
the time of laparotomy. Prompt recognition is important,
because early and aggressive treatment may limit progres-
sion of the thrombotic process. Diagnosis should be sus-
pected when acute abdominal symptoms develop in
patients with prior thrombotic episodes or a documented
coagulopathy. Early anticoagulation and aggressive ther-
apy are recommended.
Because MVT may not be suspected in many patients,
its true incidence is unknown. In autopsy studies, MVT is
found in 0.2% to 2% of the population.3,6 In a study by
Ottinger and Austen,6 MVT was found in less than 1% of
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patients with mesenteric ischemia. Commonly, patients
with MVT have abdominal pain. This can be sudden in
onset but frequently begins insidiously and worsens pro-
gressively. Mathews and White7 found that approximately
50% of patients had pain from 5 to 30 days before seeking
medical attention; 27% reported abdominal pain for more
than 1 month. The percentage of cases that progressed to
intestinal infarction is unknown. In our review, only five
(16%) of our patients had severe peritonitis resulting from
intestinal necrosis, and 10 (33%) required bowel resection.
As illustrated in Table I, recent mortality rates for
MVT are slightly lower than those from earlier series. This
may be due, in part, to early diagnosis and aggressive
treatment. Many previous reports were based on the diag-
nosis of MVT at the time of laparotomy or autopsy, thus
representing a more advanced and extensive form of MVT.
It is also possible that we now readily diagnose a more
benign form of the disease because of widespread use of
CT scanning. Improved image resolution of high-speed
CT scanning and MRI has likely added to the sensitivity of
diagnosing MVT. The apparent increase in the incidence
of MVT may be due to improved diagnostic capabilities
rather than to an actual increase in disease frequency.
A variety of hypercoagulable states are known to be
associated with MVT (Table II). Polycythemia vera and
postsplenectomy thrombocytosis (early and late postoper-
ative) have been associated with MVT, as have induced
hypercoagulable states, such as neoplastic disorders (par-
ticularly pancreatic or colonic) and heparin-induced
thrombocytopenia. An association between oral contra-
ceptive use and MVT has also been reported.8,9 Recently,
deficiencies of the vitamin K–dependent coagulation
inhibitors, proteins C and S, and decreased levels of
antithrombin III have been increasingly reported in asso-
ciation with mesenteric and portal vein thrombosis.10,11
In a previous report from this center, 56% of patients with
MVT were found to have an identifiable coagulopathy.12
Genetic variances, including activated protein C resistance
with factor V Leiden gene mutation, methylenetetrahy-
drofolate reductase mutations, and the 20210 A allele of
the prothrombin gene, have also been recently associated
with MVT.13-15
Table I. Reported series of patients with acute MVT and their management and 30-day mortality rate
30-day
Author (y) No. of patients Bowel resection Nonoperative Anticoagulation mortality rate (%)
Sack (1982)21 9 9 0 6 2 (22%)
Wilson (1987)22 16 10 3 6 8 (50%)
Montany (1988)23 6 5 1 6 3 (50%)
Clavien (1988)24 12 12 0 12 5 (42%)
Kaleya (1989)25 22 22 0 22 7 (32%)
Harward (1989)12 16 5 11 7 3 (19%)
Levy (1990)26 21 19 2 17 8 (38%)
Grieshop (1991)27 15 5 10 9 2 (13%)
Rhee (1994)5 53 30 19 33 14 (27%)
Current series (2000) 23 8 14 19 7 (30%)
Past medical or family history of thrombosis in combi-
nation with abdominal symptoms should increase the
index of suspicion for MVT. In this series, six patients had
previous deep venous or arterial thrombosis. In addition,
a hypercoagulable state is more commonly found at diag-
nosis in patients with MVT than in patients with deep
venous thrombosis. Antithrombin III deficiency has been
found to account for approximately 2% of all venous
thrombotic events. Protein C and protein S deficiencies
are commonly associated causes of the hypercoagulable
state. These two deficiencies account for approximately 5%
of venous thrombotic disorders.16 We found that 42% of
patients in our series had some form of factor deficiency
associated with hypercoagulability. Unfortunately, not all
patients, particularly before 1990, were appropriately
screened. Consequently, the incidence of hypercoagulabil-
ity is likely to be even higher.
An objective diagnosis of MVT has traditionally been
difficult to establish. Contrast-enhanced abdominal CT
scanning can accurately detect portal, ovarian vein, and
mesenteric vein thrombosis. In this series, patients under-
went CT scanning primarily or when other evaluations
were nondiagnostic. CT was diagnostic in 90% of patients
who underwent the test. CT diagnosed MVT in 15
(100%) of 15 patients presenting with vague abdominal
pain or diarrhea. We no longer recommend venous phase
mesenteric angiography as a primary diagnostic modality.
The role of duplex ultrasonography and MR angiography
remains to be defined.
Although the natural history of MVT is unknown, it
does appear not to have the ominous prognosis associated
with arterial thrombosis. In this review, the early (< 30
day) mortality rate was 23%, and only two of 31 died of
massive bowel infarction. Extended follow-up on 24
patients (average, 57.7 months) found that 21 (88%) of 24
survived long term.
Treatment ranged from observation with or without
anticoagulation and bowel rest to surgical resection of
bowel. Although thrombectomy of MVT has been
described in the literature,17,18 only one patient in this
series underwent mesenteric venous thrombectomy along
with bowel resection. Several other groups have reported
success with intra-arterial or intramesenteric venous lytic
therapy. These series have been limited, and long-term fol-
low-up for this therapeutic modality is nonexistent.19,20
Similarly, because our experience is limited, we recom-
mend further evaluation before rejecting or condoning
these forms of therapy.
MVT should be suspected in patients presenting with
abdominal pain, especially in those with histories of hyper-
coagulable disorders, deep venous thrombosis, or previous
abdominal surgery (particularly splenectomy), and these
patients should undergo contrast-enhanced CT scanning
with close attention to the mesenteric venous phase. Early
anticoagulation with heparin followed by long-term
Coumadin is recommended to limit thrombosis and
reduce the likelihood of recurrence. Full hypercoagulabil-
ity screening should also be performed in patients with a
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diagnosis of MVT. Properly treated, patients with MVT
should have a good long-term prognosis.
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